Unknown

Dataset Information

0

FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma.


ABSTRACT: BACKGROUND:FAS-670 A>G (rs1800682) and FASL-844 C>T (rs763110) polymorphisms have been previously correlated with clinical outcome of non-small cell lung cancer (NSCLC) and breast and bladder cancers. We investigated the influence of these polymorphisms on clinical outcome of malignant pleural mesothelioma (MPM) patients. PATIENTS AND METHODS:In this cohort study (NCT02269878), 68 epithelioid MPM Egyptian patients treated with first-line platinum-based chemotherapy were recruited in the period between April 2014 and May 2015. The genotype analysis was performed using TaqMan® single-nucleotide polymorphism genotyping assay. The association between the selected polymorphisms and response rate, progression-free survival (PFS) and overall survival (OS) at 18 months was evaluated. RESULTS:The median age of patients was 55 years and 45.6% of them received platinum in combination with pemetrexed, while 54.4% received platinum in combination with gemcitabine. FASL-844 CC genotype was more common than expected in early-stage tumor (P=0.042). It was found that there was no association between the investigated polymorphisms and response rate or 18-month OS. However, the PFS rate at 18 months for FASL-844 CC genotype carriers was 45% versus 10.6% for FASL-844 CT/TT genotypes carriers (log-rank: 6.2; P=0.013). Also, the number of platinum-based cycles and tumor stage were found to be significant variables for PFS by univariate analysis (P?0.001 and P=0.006, respectively). Stratified Cox regression showed that the carriers of FASL-844 CT/TT genotypes were still more susceptible to disease progression than carriers of FASL-844 CC genotype (adjusted HR =3.77, 95% CI: 1.34-10.62, P=0.012). CONCLUSION:The results of this study suggest that FASL-844 C/T polymorphism could predict PFS in MPM patients receiving platinum-based chemotherapy; therefore, this should be further evaluated as a potential marker for the prediction of clinical outcome in patients with MPM.

SUBMITTER: El-Hamamsy M 

PROVIDER: S-EPMC5106239 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma.

El-Hamamsy Manal M   Ghali Ramy R RR   Saad Amr S AS   Shaheen Sara M SM   Salem Ahmed M AM  

OncoTargets and therapy 20161107


<h4>Background</h4>FAS-670 A>G (rs1800682) and FASL-844 C>T (rs763110) polymorphisms have been previously correlated with clinical outcome of non-small cell lung cancer (NSCLC) and breast and bladder cancers. We investigated the influence of these polymorphisms on clinical outcome of malignant pleural mesothelioma (MPM) patients.<h4>Patients and methods</h4>In this cohort study (NCT02269878), 68 epithelioid MPM Egyptian patients treated with first-line platinum-based chemotherapy were recruited  ...[more]

Similar Datasets

| S-EPMC4171622 | biostudies-literature
| S-EPMC4078035 | biostudies-literature
| S-EPMC10889779 | biostudies-literature
| S-EPMC5497103 | biostudies-literature
| S-EPMC5613362 | biostudies-literature
2005-06-01 | GSE2549 | GEO
| S-EPMC6043883 | biostudies-literature
| S-EPMC6009654 | biostudies-literature
| S-EPMC7354152 | biostudies-literature
| S-EPMC4272261 | biostudies-other